primary angioplasty

¿La elevación de marcadores luego de una angioplastia electiva no debería preocuparnos?

Always in Favor of Primary Angioplasty, Even in the Pandemic Era

Compared with fibrinolytic therapy, reperfusion through primary angioplasty is more reliable and durable, and has less complications. This results in a higher net clinical benefit, both in terms of mortality and of reinfarction and bleeding. In the midst of the COVID-19 pandemic, the discussion on the usefulness of thrombolysis has emerged once again. Some societies<a href="https://solaci.org/en/2020/05/15/always-in-favor-of-primary-angioplasty-even-in-the-pandemic-era/" title="Read more" >...</a>

La ATC es una alternativa válida en el TCI

16 Years of Superiority of Primary Angioplasty

The DANish Acute Myocardial Infarction 2 (DANAMI-2) trial showed the 30-day superiority of patient transport to a primary angioplasty site vs. fibrinolysis at the hospital where the patient had been originally admitted. Those 30-day results became a landmark in the history of interventional cardiology. However, some suspected that such initial benefit could fade away over<a href="https://solaci.org/en/2020/03/27/16-years-of-superiority-of-primary-angioplasty/" title="Read more" >...</a>

ESC 2019 | CONDI-2ERIC-PPCI: punto final para el pre-acondicionamiento isquémico en angioplastia primaria

ESC 2019 | CONDI-2ERIC-PPCI: Final Blow Against Ischemic Pre-Conditioning in Primary Angioplasty

Remote ischemic conditioning does not offer any clinical benefit to patients with ST-segment elevation acute myocardial infarction undergoing primary angioplasty, according to this study presented on Sunday at the European Society of Cardiology Congress 2019. Prior studies were limited and small, but this analysis seems to provide definitive evidence with regard to ischemic pre-conditioning. The<a href="https://solaci.org/en/2019/09/05/esc-2019-condi-2eric-ppci-final-blow-against-ischemic-pre-conditioning-in-primary-angioplasty/" title="Read more" >...</a>

farmacoinvasive strategy pci

SOLACI-SOCIME 2018 | Primary angioplasty and cardiogenic shock

Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr. Cindy Grines, entitled “Primary angioplasty and cardiogenic shock&#8221;. &nbsp; We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

EuroPCR 2018 | Compare-Acute: FFR o angioplastia primaria en el seguimiento a 2 años de la revascularización completa

EuroPCR 2018 | Compare-Acute: FFR or Primary Angioplasty at a 2-Year Follow-Up After Complete Revascularization

Recent studies in patients undergoing acute myocardial infarction showed that a complete revascularization strategy in an acute or subacute setting, whether it be guided through angiography (PRAMI, CvLPRIT) or fractional flow reserve (FFR) (PRIMULTI, COMPARE-ACUTE), improves the combined endpoint of major adverse cardiac events (MACE) when compared with treatment of the culprit artery only. Based<a href="https://solaci.org/en/2018/05/29/compare-acute-ffr-or-primary-angioplasty-at-a-2-year-follow-up-after-complete-revascularization/" title="Read more" >...</a>

¿Cuál es la mejor antiagregación en la angioplastia primaria a 12 meses?

What Is the Best Antiplatelet Therapy in Primary Angioplasty at 12 Months?

Both prasugrel and ticagrelor showed superiority in terms of efficacy, reducing the number of major cardiovascular events at the expense of increased bleeding. This is an affordable cost, and the net clinical benefit supports these new antiplatelet therapies. The one-year follow-up of the PRAGUE-18 study focused on a comparison of efficacy and safety between prasugrel<a href="https://solaci.org/en/2018/03/07/what-is-the-best-antiplatelet-therapy-in-primary-angioplasty-at-12-months/" title="Read more" >...</a>

Trombosis-post-TAVI

Ischemic and Bleeding Risk After Primary Angioplasty

Patients with ST-segment elevation myocardial infarction who undergo primary angioplasty are at high risk for both ischemic and bleeding events, which affect significantly both morbidity and mortality. An optimal selection of antithrombotic therapies in terms of strength and duration must take into account the timing for the procedure, since the risk for these complications may<a href="https://solaci.org/en/2017/11/22/ischemic-and-bleeding-risk-after-primary-angioplasty/" title="Read more" >...</a>

COMPARE-ACUTE: FFR para guiar la revascularización de vasos no culpables en la angioplastia primaria

COMPARE-ACUTE: FFR-Guided Non-Culprit Vessel Revascularization in Primary Angioplasty

Courtesy of the SBHCI. About 50% of patients admitted with acute ST-segment elevation myocardial infarction also present lesions in another vessel. Whether to treat these or not, and the optimal moment to treat non-culprit infarction-related vessels are still controversial issues. &nbsp; The COMPARE-ACUTE study was recently published and showed that fractional flow reserve (FFR)-guided complete<a href="https://solaci.org/en/2017/06/02/compare-acute-ffr-guided-non-culprit-vessel-revascularization-in-primary-angioplasty/" title="Read more" >...</a>

ticagrelor vs prasugel

Ticagrelor vs. Prasugel: Similar Safety and Efficacy in Primary Angioplasty

No randomized head-to-head study comparing the efficacy and safety of ticagrelor and prasugrel has been carried out in the last 7&nbsp;years since these newer P2Y12 inhibitors first showed a higher efficacy relative to clopidogrel. &nbsp; This study was designed to compare the efficacy and safety of prasugrel and ticagrelor in patients with acute myocardial infarction<a href="https://solaci.org/en/2016/12/07/ticagrelor-vs-prasugel-primary-angioplasty/" title="Read more" >...</a>

Trombos residuales angioplastia primaria

Residual Thrombus After Aspiration Thrombectomy: Does It Affect the Outcome of Primary Angioplasty?

The aim of this study was to evaluate if the residual thrombus burden after aspiration thrombectomy may affect the outcome of primary angioplasty in patients with acute coronary syndrome with ST-segment elevation. &nbsp; The most recent studies on aspiration thrombectomy failed to show clinical benefit in patients with ST-segment elevation. This study is based on<a href="https://solaci.org/en/2016/10/20/residual-thrombus-after-aspiration-thrombectomy-does-it-affect-the-outcome-of-primary-angioplasty/" title="Read more" >...</a>

Top